Role of apoptosis-inducing factor, proline dehydrogenase, and NADPH oxidase in apoptosis and oxidative stress

Cell Health and Cytoskeleton

Volumn 4, Issue , 2012, Pages 11-27

  Natarajan, Sathish Kumar ^a   Becker, Donald F ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Apoptosis; Apoptosis inducing factor; Flavoproteins; NADPH oxidase; Proline dehydrogenase

Indexed keywords

APOPTOSIS INDUCING FACTOR; CYCLOPHILIN A; DNA; FLAVONE DERIVATIVE; FLAVOPROTEIN; OXIDOREDUCTASE; PROLINE DEHYDROGENASE; PROTEIN P53; PROTEIN PRECURSOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUPEROXIDE;

APOPTOSIS; BIOENERGY; CELL DEATH; CELL PROLIFERATION; DNA BINDING; DNA CLEAVAGE; ENZYME ACTIVITY; GENE DELETION; GENE MUTATION; HUMAN; MITOCHONDRIAL MEMBRANE; NEUTROPHIL; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PHAGOCYTOSIS; PROTEIN FUNCTION; REVIEW; SENSOR; UPREGULATION;

EID: 84930484351     PISSN: None     EISSN: 11791330     Source Type: Journal    
DOI: 10.2147/CHC.S4955     Document Type: Review

References (169)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239-257.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267(5203):1456-1462.
3. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397(6718): 441-446.
4. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383-424.
5. Ashkenazi A. Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat Rev Cancer. 2002;2(6):420-430.
6. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet. 1999;33: 29-55.
7. Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem. 2004;73:87-106.
8. Lorenzo HK, Susin SA. Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug Resist Updat. 2007;10(6):235-255.
9. Solary E, Droin N, Bettaieb A, Corcos L, Dimanche-Boitrel M, Garrido C. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia. 2000;14(10):1833-1849.
10. Zhang X, Vallabhaneni R, Loughran PA, et al. Changes in FADD levels, distribution, and phosphorylation in TNF alpha-induced apoptosis in hepatocytes is caspase-3, caspase-8 and BID dependent. Apoptosis. 2008;13(8):983-992.
11. Thomas LR, Stillman DJ, Thorburn A. Regulation of Fas-associated death domain interactions by the death effector domain identified by a modified reverse two-hybrid screen. J Biol Chem. 2002;277(37): 34343-34348.
12. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010;16(6):1701-1708.
13. Fan TJ, Han LH, Cong RS, Liang J. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai). 2005;37(11):719-727.
14. Ramachandran A, Madesh M, Balasubramanian KA. Apoptosis in the intestinal epithelium: its relevance in normal and pathophysiological conditions. J Gastroenterol Hepatol. 2000;15(2):109-120.
15. Sakata S, Sakamaki K, Watanabe K, et al. Involvement of death receptor Fas in germ cell degeneration in gonads of Kit-deficient Wv/Wv mutant mice. Cell Death Differ. 2003;10(6):676-686.
16. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37(3):299-310.
17. Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol. 2007;8(5):405-413.
18. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27(48): 6194-6206.
19. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature. 2001;412(6842):95-99.
20. Li H, Zhu H, Xu C, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94(4):491-501.
21. Ott M, Norberg E, Zhivotovsky B, Orrenius S. Mitochondrial targeting of tBid/Bax: a role for the TOM complex? Cell Death Differ. 2009;16(8):1075-1082.
22. Festjens N, van Gurp M, Van Loo G, Saelens X, Vandenabeele P. Bcl-2 family members as sentinels of cellular integrity and role of mitochondrial intermembrane space proteins in apoptotic cell death. Acta Haematol. 2004;111(1-2):7-27.
23. Yin XM. Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene. 2006;369(1):7-19.
24. Llambi F, Green DR. Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev. 2011;21(1):12-20.
25. Chen M, He H, Zhan S, Krajewski S, Reed JC, Gottlieb RA. Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. J Biol Chem. 2001;276(33):30724-30728.
26. Joza N, Pospisilik JA, Hangen E, et al. AIF: not just an apoptosisinducing factor. Ann N Y Acad Sci. 2009;1171:2-11.
27. Delavallée L, Cabon L, Galán Malo P, Lorenzo HK, Susin SA. AIF mediated caspase independent necroptosis: A new chance for targeted therapeutics. IUBMB Life. 2011;63(4):221-232.
28. Sevrioukova IF. Redox-linked conformational dynamics in apoptosisinducing factor. J Mol Biol. 2009;390(5):924-938.
29. Ye H, Cande C, Stephanou NC, et al. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat Struct Biol. 2002;9(9):680-684.
30. Sevrioukova IF. Apoptosis-inducing factor: structure, function, and redox regulation. Antioxid Redox Signal. 2011;14(12):2545-2579.
31. Ghezzi D, Sevrioukova I, Invernizzi F, et al. Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosisinducing factor. Am J Hum Genet. 2010;86(4):639-649.
32. Miramar MD, Costantini P, Ravagnan L, et al. NADH oxidase activity of mitochondrial apoptosis-inducing factor. J Biol Chem. 2001;276(19):16391-16398.
33. Churbanova IY, Sevrioukova IF. Redox-dependent changes in molecular properties of mitochondrial apoptosis-inducing factor. J Biol Chem. 2008;283(9):5622-5631.
34. Miseviciene L, Anusevicius Z, Sarlauskas J, Sevrioukova IF, Cenas N. Redox reactions of the FAD-containing apoptosis-inducing factor (AIF) with quinoidal xenobiotics: a mechanistic study. Arch Biochem Biophys. 2011;512(2):183-189.
35. Klein JA, Longo-Guess CM, Rossmann MP, et al. The hHarlequin mouse mutation downregulates apoptosis-inducing factor. Nature. 2002;419(6905):367-374.
36. Vahsen N, Cande C, Briere JJ, et al. AIF deficiency compromises oxidative phosphorylation. EMBO J. 2004;23(23):4679-4689.
37. Pospisilik JA, Knauf C, Joza N, et al. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell. 2007;131(3):476-491.
38. Koene S, Willems PH, Roestenberg P, Koopman WJ, Smeitink JA. Mouse models for nuclear DNA-encoded mitochondrial complex I deficiency. J Inherit Metab Dis. 2011;34(2):293-307.
39. Brown D, Yu BD, Joza N, et al. Loss of AIF function causes cell death in the mouse embryo, but the temporal progression of patterning is normal. Proc Natl Acad Sci U S A. 2006;103(26):9918-9923.
40. Culmsee C, Zhu C, Landshamer S, et al. Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J Neurosci. 2005;25(44):10262-10272.
41. Joza N, Susin SA, Daugas E, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 2001;410(6828):549-554.
42. Apostolova N, Cervera AM, Victor VM, et al. Loss of apoptosisinducing factor leads to an increase in reactive oxygen species, and an impairment of respiration that can be reversed by antioxidants. Cell Death Differ. 2006;13(2):354-357.
43. Krantic S, Mechawar N, Reix S, Quirion R. Apoptosis-inducing factor: a matter of neuron life and death. Prog Neurobiol. 2007;81(3): 179-196.
44. Urbano A, Lakshmanan U, Choo PH, et al. AIF suppresses chemical stress-induced apoptosis and maintains the transformed state of tumor cells. EMBO J. 2005;24(15):2815-2826.
45. Modjtahedi N, Giordanetto F, Madeo F, Kroemer G. Apoptosis-inducing factor: vital and lethal. Trends Cell Biol. 2006;16(5):264-272.
46. Mate MJ, Ortiz-Lombardia M, Boitel B, et al. The crystal structure of the mouse apoptosis-inducing factor AIF. Nat Struct Biol. 2002;9(6): 442-446.
47. Vahsen N, Cande C, Dupaigne P, et al. Physical interaction of apoptosis-inducing factor with DNA and RNA. Oncogene. 2006; 25(12):1763-1774.
48. Montague JW, Gaido ML, Frye C, Cidlowski JA. A calcium-dependent nuclease from apoptotic rat thymocytes is homologous with cyclophilin. Recombinant cyclophilins A, B, and C have nuclease activity. J Biol Chem. 1994;269(29):18877-18880.
49. Candé C, Vahsen N, Kouranti I, et al. AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. Oncogene. 2004;23(8):1514-1521.
50. Artus C, Boujrad H, Bouharrour A, et al. AIF promotes chromatinolysis and caspase-independent programmed necrosis by interacting with histone H2AX. EMBO J. 2010;29(9):1585-1599.
51. Liu L, Xing D, Chen WR. Micro-calpain regulates caspasedependent and apoptosis inducing factor-mediated caspase-independent apoptotic pathways in cisplatin-induced apoptosis. Int J Cancer. 2009;125(12):2757-2766.
52. Yuste VJ, Moubarak RS, Delettre C, et al. Cysteine protease inhibition prevents mitochondrial apoptosis-inducing factor (AIF) release. Cell Death Differ. 2005;12(11):1445-1448.
53. Ravagnan L, Gurbuxani S, Susin SA, et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol. 2001;3(9):839-843.
54. Desmots F, Russell HR, Michel D, McKinnon PJ. Scythe regulates apoptosis-inducing factor stability during endoplasmic reticulum stressinduced apoptosis. J Biol Chem. 2008;283(6):3264-3271.
55. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science. 2002;297(5579):259-263.
56. Wang Y, Dawson VL, Dawson TM. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol. 2009;218(2):193-202.
57. Wang Y, Kim NS, Haince JF, et al. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal. 2011;4(167):RA20.
58. Yu SW, Wang Y, Frydenlund DS, Ottersen OP, Dawson VL, Dawson TM. Outer mitochondrial membrane localization of apoptosisinducing factor: mechanistic implications for release. ASN Neuro. 2009;1(5):e00021.
59. Zanna C, Ghelli A, Porcelli AM, et al. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain. 2008;131(Pt 2):352-367.
60. Jendrossek V, Fillon S, Belka C, Muller I, Puttkammer B, Lang F. Apoptotic response of Chang cells to infection with Pseudomonas aeruginosa strains PAK and PAO-I: molecular ordering of the apoptosis signaling cascade and role of type IV pili. Infect Immun. 2003;71(5):2665-2673.
61. Choi CH, Lee EY, Lee YC, et al. Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells. Cell Microbiol. 2005;7(8):1127-1138.
62. Ashktorab H, Dashwood RH, Dashwood MM, et al. H. pylori induced apoptosis in human gastric cancer cells mediated via the release of apoptosis inducing factor from mitochondria. Helicobacter. 2008;13(6):506-517.
63. Flynn AN, Wang A, McKay DM, Buret AG. Apoptosis-inducing factor contributes to epithelial cell apoptosis induced by enteropathogenic Escherichia coli. Can J Physiol Pharmacol. 2011;89(2):143-148.
64. Flynn AN, Buret AG. Tight junctional disruption and apoptosis in an in vitro model of Citrobacter rodentium infection. Microb Pathog. 2008;45(2):98-104.
65. Suemasu S, Tanaka K, Namba T, et al. A role for HSP70 in protecting against indomethacin-induced gastric lesions. J Biol Chem. 2009;284(29):19705-19715.
66. Matsumori Y, Hong SM, Aoyama K, et al. Hsp70 overexpression sequesters AIF and reduces neonatal hypoxic/ischemic brain injury. J Cereb Blood Flow Metab. 2005;25(7):899-910.
67. Choudhury S, Bae S, Ke Q, Lee JY, Kim J, Kang PM. Mitochondria to nucleus translocation of AIF in mice lacking Hsp70 during ischemia/reperfusion. Basic Res Cardiol. 2011;106(3):397-407.
68. Pae CU, Kim TS, Kwon OJ, et al. Polymorphisms of heat shock protein 70 gene (HSPA1A, HSPA1B and HSPA1L) and schizophrenia. Neurosci Res. 2005;53(1):8-13.
69. Xiao CY, Chen M, Zsengeller Z, Szabo C. Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosisinducing factor. J Pharmacol Exp Ther. 2004;310(2):498-504.
70. Millan A, Huerta S. Apoptosis-inducing factor and colon cancer. J Surg Res. 2009;151(1):163-170.
71. Schmitt E, Maingret L, Puig PE, et al. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 2006;66(8):4191-4197.
72. Hamasaki M, Hideshima T, Tassone P, et al. Azaspirane (NN-diethyl-8, 8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005;105(11):4470-4476.
73. Wang M, Zhang L, Han X, et al. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007;109(12):5455-5462.
74. Park YC, Jeong JH, Park KJ, et al. Sulindac activates nuclear translocation of AIF, DFF40 and endonuclease G but not induces oligonucleosomal DNA fragmentation in HT-29 cells. Life Sci. 2005;77(16):2059-2070.
75. Phang JM, Donald SP, Pandhare J, Liu Y. The metabolism of proline, a stress substrate, modulates carcinogenic pathways. Amino Acids. 2008;35(4):681-690.
76. Arentson BW, Sanyal N, Becker DF. Substrate channeling in proline metabolism. Front Biosci. 2012;17:375-388.
77. Phang JM, Liu W, Zabirnyk O. Proline metabolism and microenvironmental stress. Annu Rev Nutr. 2010;30:441-463.
78. Small WC, Jones ME. Pyrroline 5-carboxylate dehydrogenase of the mitochondrial matrix of rat liver. Purification, physical and kinetic characteristics. J Biol Chem. 1990;265(30):18668-18672.
79. Tanner JJ. Structural biology of proline catabolism. Amino Acids. 2008;35(4):719-730.
80. Zhang M, White TA, Schuermann JP, Baban BA, Becker DF, Tanner JJ. Structures of the Escherichia coli PutA proline dehydrogenase domain in complex with competitive inhibitors. Biochemistry. 2004;43(39):12539-12548.
81. White TA, Krishnan N, Becker DF, Tanner JJ. Structure and kinetics of monofunctional proline dehydrogenase from Thermus thermophilus. J Biol Chem. 2007;282(19):14316-14327.
82. Moxley MA, Tanner JJ, Becker DF. Steady-state kinetic mechanism of the proline: ubiquinone oxidoreductase activity of proline utilization A (PutA) from Escherichia coli. Arch Biochem Biophys. 2011;516(2):113-120.
83. Lee YH, Nadaraia S, Gu D, Becker DF, Tanner JJ. Structure of the proline dehydrogenase domain of the multifunctional PutA flavoprotein. Nat Struct Biol. 2003;10(2):109-114.
84. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997;389(6648):300-305.
85. Donald SP, Sun XY, Hu CA, et al. Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species. Cancer Res. 2001;61(5):1810-1815.
86. Maxwell SA, Davis GE. Differential gene expression in p53-mediated apoptosis-resistant vs apoptosis-sensitive tumor cell lines. Proc Natl Acad Sci U S A. 2000;97(24):13009-13014.
87. Pandhare J, Cooper SK, Phang JM. Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferatoractivated receptor gamma-dependent and-independent mechanisms. J Biol Chem. 2006;281(4):2044-2052.
88. Pandhare J, Donald SP, Cooper SK, Phang JM. Regulation and function of proline oxidase under nutrient stress. J Cell Biochem. 2009;107(4):759-768.
89. Maxwell SA, Kochevar GJ. Identification of a p53-response element in the promoter of the proline oxidase gene. Biochem Biophys Res Commun. 2008;369(2):308-313.
90. Cooper SK, Pandhare J, Donald SP, Phang JM. A novel function for hydroxyproline oxidase in apoptosis through generation of reactive oxygen species. J Biol Chem. 2008;283(16):10485-10492.
91. Phang JM, Pandhare J, Zabirnyk O, Liu Y. PPARgamma and proline oxidase in cancer. PPAR Res. 2008;2008:542694.
92. Liu Y, Borchert GL, Surazynski A, Hu CA, Phang JM. Proline oxidase activates both intrinsic and extrinsic pathways for apoptosis: the role of ROS/superoxides, NFAT and MEK/ERK signaling. Oncogene. 2006;25(41):5640-5647.
93. Liu Y, Borchert G, Surazynski A, Phang J. Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. Oncogene. 2008;27(53):6729-6737.
94. Hu CA, Phang JM, Valle D. Proline metabolism in health and disease. Preface. Amino Acids. 2008;35(4):651-652.
95. Hu CA, Donald SP, Yu J, et al. Overexpression of proline oxidase induces proline-dependent and mitochondria-mediated apoptosis. Mol Cell Biochem. 2007;295(1-2):85-92.
96. Liu Y, Borchert GL, Donald SP, et al. MnSOD inhibits proline oxidase-induced apoptosis in colorectal cancer cells. Carcinogenesis. 2005;26(8):1335-1342.
97. Zou W, Liu X, Yue P, Khuri FR, Sun SY. PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther. 2007;6(1):99-106.
98. Elrod HA, Sun SY. PPARgamma and apoptosis in cancer. PPAR Res. 2008;2008:704165.
99. Miller G, Honig A, Stein H, Suzuki N, Mittler R, Zilberstein A. Unraveling delta1-pyrroline-5-carboxylate-proline cycle in plants by uncoupled expression of proline oxidation enzymes. J Biol Chem. 2009;284(39):26482-26492.
100. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21-35.
101. Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle. 2010;9(6):1091-1096.
102. Krishnan N, Becker DF, Dickman MB. Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress. Free Radical Biol Med. 2008;44(4): 671-681.
103. Liu W, Zabirnyk O, Wang H, et al. miR-23b* targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene. 2010;29(35):4914-4924.
104. Willis A, Bender HU, Steel G, Valle D. PRODH variants and risk for schizophrenia. Amino Acids. 2008;35(4):673-679.
105. Jacquet H, Demily C, Houy E, et al. Hyperprolinemia is a risk factor for schizoaffective disorder. Mol Psychiatry. 2005;10(5): 479-485.
106. Jacquet H, Raux G, Thibaut F, et al. PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum Mol Genet. 2002;11(19):2243-2249.
107. Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci. 2010;11(6):402-416.
108. Bender HU, Almashanu S, Steel G, et al. Functional consequences of PRODH missense mutations. Am J Hum Genet. 2005;76(3):409-420.
109. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001;357(Pt 3): 593-615.
110. Nakajima K, Inatsu S, Mizote T, et al. Possible involvement of put A gene in Helicobacter pylori colonization in the stomach and motility. Biomed Res. 2008;29(1):9-18.
111. Krishnan N, Doster AR, Duhamel GE, Becker DF. Characterization of a Helicobacter hepaticus putA mutant strain in host colonization and oxidative stress. Infect Immun. 2008;76(7):3037-3044.
112. Brown DI, Griendling KK. Nox proteins in signal transduction. Free Radic Biol Med. 2009;47(9):1239-1253.
113. Kakinuma K, Kaneda M, Chiba T, Ohnishi T. Electron spin resonance studies on a flavoprotein in neutrophil plasma membranes. Redox potentials of the flavin and its participation in NADPH oxidase. J Biol Chem. 1986;261(20):9426-9432.
114. Cross AR, Jones OTG, Harper AM, Segal AW. Oxidation-reduction properties of the cytochrome-B found in the plasma-membrane fraction of human-neutrophils-a possible oxidase in the respiratory burst. Biochem J. 1981;194(2):599-606.
115. Fulton DJ. Nox5 and the regulation of cellular function. Antioxid Redox Signal. 2009;11(10):2443-2452.
116. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011;10(6):453-471.
117. Jiang F, Zhang Y, Dusting GJ. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev. 2011;63(1):218-242.
118. Takeya R, Ueno N, Kami K, et al. Novel human homologues of p47phox and p67phox participate in activation of superoxideproducing NADPH oxidases. J Biol Chem. 2003;278(27): 25234-25246.
119. Ueyama T, Tatsuno T, Kawasaki T, et al. A regulated adaptor function of p40phox: distinct p67phox membrane targeting by p40phox and by p47phox. Mol Biol Cell. 2007;18(2):441-454.
120. Johnson JL, Park JW, Benna JE, Faust LRP, Inanami O, Babior BM. Activation of p47 phox, a cytosolic subunit of the leukocyte NADPH oxidase. J Biol Chem. 1998;273(52):35147-35152.
121. Hoyal CR, Gutierrez A, Young BM, et al. Modulation of p47PHOX activity by site-specific phosphorylation: Akt-dependent activation of the NADPH oxidase. Proc Natl Acad Sci U S A. 2003;100(9):5130-5135.
122. Lopes LR, Dagher MC, Gutierrez A, et al. Phosphorylated p40PHOX as a negative regulator of NADPH oxidase. Biochemistry. 2004;43(12):3723-3730.
123. Kim KA, Kim JY, Lee YA, Song KJ, Min D, Shin MH. NOX1 participates in ROS-dependent cell death of colon epithelial Caco2 cells induced by Entamoeba histolytica. Microbes Infect. 2011;13(12-13):1052-1061.
124. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A. 2010;107(35):15565-15570.
125. Weyemi U, Lagente-Chevallier O, Boufraqech M, et al. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene. August 15, 2011. [Epub ahead of print.]
126. Babior BM. NADPH oxidase. Curr Opin Immunol. 2004;16(1): 42-47.
127. Ris-Stalpers C. Physiology and pathophysiology of the DUOXes. Antioxid Redox Signal. 2006;8(9-10):1563-1572.
128. Pendyala S, Natarajan V. Redox regulation of Nox proteins. Respir Physiol Neurobiol. 2010;174(3):265-271.
129. Yu JH, Kim KH, Kim H. Role of NADPH oxidase and calcium in cerulein-induced apoptosis: involvement of apoptosis-inducing factor. Ann N Y Acad Sci. 2006;1090:292-297.
130. Matsuzawa A, Saegusa K, Noguchi T, et al. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol. 2005;6(6): 587-592.
131. Basuroy S, Bhattacharya S, Leffler CW, Parfenova H. Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. Am J Physiol Cell Physiol. 2009;296(3):C422-C432.
132. Noguchi T, Ishii K, Fukutomi H, et al. Requirement of reactive oxygen species-dependent activation of ASK1-p38 MAPK pathway for extracellular ATP-induced apoptosis in macrophage. J Biol Chem. 2008;283(12):7657-7665.
133. Park KJ, Lee CH, Kim A, Jeong KJ, Kim CH, Kim YS. Death receptors 4 and 5 activate Nox1 NADPH oxidase through riboflavin kinase to induce reactive oxygen species-mediated apoptotic cell death. J Biol Chem. December 9, 2011. [Epub ahead of print.]
134. Mustapha NM, Tarr JM, Kohner EM, Chibber R. NADPH oxidase versus mitochondria-derived ROS in glucose-induced apoptosis of pericytes in early diabetic retinopathy. J Ophthalmol. 2010; 2010:746978.
135. Nakano Y, Longo-Guess CM, Bergstrom DE, Nauseef WM, Jones SM, Banfi B. Mutation of the Cyba gene encoding p22phox causes vestibular and immune defects in mice. J Clin Invest. 2008; 118(3):1176-1185.
136. de Oliveira-Junior EB, Bustamante J, Newburger PE, Condino-Neto A. The human NADPH oxidase: primary and secondary defects impairing the respiratory burst function and the microbicidal ability of phagocytes. Scand J Immunol. 2011;73(5):420-427.
137. Cave AC, Brewer AC, Narayanapanicker A, et al. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal. 2006;8(5-6):691-728.
138. Griffith B, Pendyala S, Hecker L, Lee PJ, Natarajan V, Thannickal VJ. NOX enzymes and pulmonary disease. Antioxid Redox Signal. 2009;11(10):2505-2516.
139. Sorescu D, Weiss D, Lassegue B, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002;105(12):1429-1435.
140. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 2008;266(1):37-52.
141. Grishko V, Pastukh V, Solodushko V, Gillespie M, Azuma J, Schaffer S. Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. Am J Physiol Heart Circ Physiol. 2003;285(6):H2364-H2372.
142. Sheehan AL, Carrell S, Johnson B, Stanic B, Banfi B, Miller FJ Jr. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis. 2011;216(2):321-326.
143. Heinloth A, Heermeier K, Raff U, Wanner C, Galle J. Stimulation of NADPH oxidase by oxidized low-density lipoprotein induces proliferation of human vascular endothelial cells. J Am Soc Nephrol. 2000;11(10):1819-1825.
144. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III2-III7.
145. Gotoh N, Niki E. Rates of interactions of superoxide with vitamin E, vitamin C and related compounds as measured by chemiluminescence. Biochim Biophys Acta. 1992;1115(3):201-207.
146. Loughlin DT, Artlett CM. Precursor of advanced glycation end products mediates ER-stress-induced caspase-3 activation of human dermal fibroblasts through NAD(P)H oxidase 4. PLoS One. 2010;5(6):e11093.
147. Jaquet V, Scapozza L, Clark RA, Krause KH, Lambeth JD. Smallmolecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal. 2009;11(10):2535-2552.
148. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today. 2006;11(12): 524-533.
149. Guichard C, Moreau R, Pessayre D, Epperson TK, Krause KH. NOX family NADPH oxidases in liver and in pancreatic islets: a role in the metabolic syndrome and diabetes. Biochem Soc Trans. 2008;36(Pt 5): 920-929.
150. Leto TL, Morand S, Hurt D, Ueyama T. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid Redox Signal. 2009;11(10):2607-2619.
151. Kim JA, Neupane GP, Lee ES, Jeong BS, Park BC, Thapa P. NADPH oxidase inhibitors: a patent review. Expert Opin Ther Pat. 2011;21(8):1147-1158.
152. Guimaraes EL, Empsen C, Geerts A, van Grunsven LA. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol. 2010;52(3):389-397.
153. Ping J, Li JT, Liao ZX, Shang L, Wang H. Indole-3-carbinol inhibits hepatic stellate cells proliferation by blocking NADPH oxidase/reactive oxygen species/p38 MAPK pathway. Eur J Pharmacol. 2011;650(2-3):656-662.
154. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol. 2003;38(1):S38-S53.
155. Cui W, Matsuno K, Iwata K, et al. NOX1/nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase promotes proliferation of stellate cells and aggravates liver fibrosis induced by bile duct ligation. Hepatology. 2011;53(3):948-958.
156. Masamune A, Watanabe T, Kikuta K, Satoh K, Shimosegawa T. NADPH oxidase plays a crucial role in the activation of pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G99-G108.
157. Govindarajan B, Sligh JE, Vincent BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest. 2007;117(3):719-729.
158. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, Gukovskaya AS. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem. 2004;279(33): 34643-34654.
159. Eid AA, Ford BM, Block K, et al. AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J Biol Chem. 2010;285(48):37503-37512.
160. Brar SS, Corbin Z, Kennedy TP, et al. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. Am J Physiol Cell Physiol. 2003;285(2):C353-C369.
161. Jiang Z, Fletcher NM, Ali-Fehmi R, et al. Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells. Gynecol Oncol. 2011;122(2):418-423.
162. Tew DG. Inhibition of cytochrome P450 reductase by the diphenyliodonium cation. Kinetic analysis and covalent modifications. Biochemistry. 1993;32(38):10209-10215.
163. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87(1):245-313.
164. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol. 1994;11(1):95-102.
165. Heumüller S, Wind S, Barbosa-Sicard E, et al. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension. 2008;51(2):211-217.
166. Vejrazka M, Micek R, Stipek S. Apocynin inhibits NADPH oxidase in phagocytes but stimulates ROS production in non-phagocytic cells. Biochim Biophys Acta. 2005;1722(2):143-147.
167. Yamamoto A, Kami K, Takeya R, Sumimoto H. Interaction between the SH3 domains and C-terminal proline-rich region in NADPH oxidase organizer 1 (Noxo1). Biochem Biophys Res Commun. 2007;352(2):560-565.
168. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res. 2001;89(5):408-414.
169. Laleu B, Gaggini F, Orchard M, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem. 2010;53(21):7715-7730.